A Pilot Open-Label Phase II Trial of Rituximab for Non-Criteria Manifestations of Antiphospholipid Syndrome
ABSTRACT BACKGROUND: Few studies address the treatment of non-criteria manifestations of antiphospholipid syndrome (APS). METHODS: The primary objective of this 12-month pilot, Phase II study was to evaluate the safety of rituximab in antiphospholipid antibody (aPL)-positive patients with non-criteria APS manifestations. The secondary objectives were to evaluate the effect of rituximab on aPL profile and non-criteria APS manifestations. Adult aPL-positive patients with thrombocytopenia, cardiac valve disease (CVD), skin ulcer, aPL-nephropathy (aPLN), and/or cognitive dysfunction (CD) received two doses of rituximab (1000mg) on days one and 15. Antiphospholipid antibody profiles and clinical outcome measures (COMs) were analyzed at preset time points, which were categorized as: "complete response (CR)", "partial response (PR)", "no response (NR)", and "recurrence (RC)". RESULTS: Two of 19 patients developed infusion reactions resulting in early termination. There were 12 serious and 49 non-serious adverse events. All patients with baseline positive lupus anticoagulant as well as anticardiolipin and anti-β(2) -glycoprotein-I antibody IgG tests remained positive at 24 and 52 weeks. The number of patients with CR/PR/NR/RC for COMs at 24 weeks was: 1/1/2/0 for thrombocytopenia; 0/0/3/- for CVD; 3/1/0/1 for skin ulcer; 0/1/0/0 for aPLN; and 3/1/1/- for CD. CONCLUSION: Our uncontrolled and non-randomized pilot study suggests that safety is consistent with rituximab's safety profile in aPL-positive patients; and despite no substantial change in aPL profiles, rituximab may be effective in controlling some but not all non-criteria aPL manifestations. © 2012 American College of Rheumatology.
- SourceAvailable from: Rohan WillisAntiphospholipid Syndrome, 04/2012; , ISBN: 978-953-51-0526-8
- [Show abstract] [Hide abstract]
ABSTRACT: The antiphospholipid syndrome is characterized by a combination of laboratory findings (i.e., the presence of at least one antiphospholipid antibody) and clinical manifestations (arterial and/or venous thrombosis, obstetrical complications). Long-term oral anticoagulant is recommended to prevent recurrence of both arterial and venous thrombosis, whereas (low molecular weight) heparin plus aspirin is the treatment of choice to prevent further obstetrical complications. In the rare case of catastrophic antiphospholipid syndrome, heparin plus high-dose corticosteroids plus plasma exchange is associated with the highest recovery rate. Some new, non-antithrombotic-based treatments of antiphospholipid syndrome with rituximab, autologous stem cell transplantation, or hydroxychloroquine are also reviewed.06/2013; 5(1):1-7. DOI:10.1007/s13317-013-0056-5
- [Show abstract] [Hide abstract]
ABSTRACT: The catastrophic variant of the antiphospholipid syndrome (APS) is characterized by thrombosis in multiple organs developing over a short period of time. First-line treatment for the catastrophic APS is the combination of anticoagulation plus corticosteroids plus plasma exchange and/or intravenous immunoglobulin. Despite this regimen, the mortality remains high and new treatment options are needed. By a systematic review of the catastrophic APS Registry (CAPS Registry), we identified 20 patients treated with rituximab. The purpose of this study is to describe the clinical manifestations, laboratory features, and outcomes of rituximab-treated CAPS patients. In addition, the rationale for using rituximab in catastrophic APS is discussed.Autoimmunity reviews 06/2013; DOI:10.1016/j.autrev.2013.05.004 · 7.10 Impact Factor